EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application pregabalin capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. Aurobindo Pharma’s pregabalin capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Lyrica Capsules manufactured by Upjohn US 2 LLC.

Pregabalin capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures, management of fibromyalgia, management of neuropathic pain associated with spinal cord injury.

Pregabalin capsules has an estimated market size of US $238 Million for the twelve months ending January 2023, as per IQVIA.